REGULATORY

• LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
  February 26, 2025

• Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
  February 26, 2025

• Care Avoidance from Copay Cap Hike Likely to Result in 195 Billion Yen Cost Reduction
  February 25, 2025

• PMDA Lists Info Needed for Pediatric Development Plan Confirmation
  February 25, 2025

• MHLW to Shorten Procedure for Generic Product Integration to 1.5 Months
  February 21, 2025

• Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
  February 21, 2025

• Japan to Pen Fact Sheet for Sanofi’s High-Dose Flu Jab
  February 21, 2025

• Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
  February 21, 2025

• Ex-Lawmakers Launch Council for Revamping Japan’s Drug Innovation
  February 20, 2025

• Chuikyo OKs Pricing Rules for FY2025 Drug Price Revision
  February 20, 2025

• CDP Submits Bill Calling for Outright Freeze on Copay Cap Reform
  February 20, 2025

• Sakigake Tag Withdrawn for 2 Boehringer Drugs
  February 20, 2025

• Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
  February 20, 2025

• Ishiba Vows to Take Steps on OTC-Like Meds from FY2026, Freeze Certain Hikes in Copay Caps
  February 19, 2025

• Japan Cabinet OKs 5-Year Healthcare Strategy from FY2025
  February 19, 2025

• Minister Touts “Balanced” Off-Year Revision after USCC Letter
  February 19, 2025

• Espha’s Januvia Generic on Approval Roster towards June Listing
  February 18, 2025

• “Annual Reports” Allowed for CMC Changes with Minimal Impact: MHLW
  February 17, 2025

• Japan to Approve EquMet Generics, More Copycats toward June Listing
  February 17, 2025

• MHLW Lays Out Procedures for Transition to Trivalent Flu Shots
  February 17, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• …
• Next ›
• 最終 »